While the demonstrated efficacy of TDXd has led to its implementation in clinical practice broadly for patients with metastatic HER2+ or HER2-low breast cancer, it has been associated with important toxicities that require close observation. The gene discussed is ERBB2; the disease is breast carcinoma.